Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845352 | 1.00 | ALDH1A1 (0.59) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL7440685 | 0.95 | ALDH1A1 (0.53) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL28739289 | 0.84 | CYP2C9 (0.53) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL2369774 | 0.83 | ALDH1A1 (0.57) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL28140482 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL6051357 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL328867 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL28192 | 0.79 | ALDH1A1 (0.74) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL5285943 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD | |
| SCHEMBL7437199 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| CN-101622241-B | Benzimidazole compound and medical application thereof | MITSUBISHI TANABE PHARMA CORP | 2013-05-22 | — | — | CN | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| CN-101622241-A | Benzimidazole compound and medical application thereof | MITSUBISHI TANABE PHARMA CORP | 2010-01-06 | — | — | CN | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1255758-A1 | APOPTOSIS-INDUCING COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2002-11-13 | — | — | EP | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001058904-A1 | APOPTOSIS-INDUCING COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2001-08-16 | — | — | WO | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998050346-A2 | ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| EP-0482080-B1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS | GENENTECH INC (US) | 1997-03-26 | — | — | EP | disclosed |
| EP-0555328-A1 | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007870-A1 | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0482080-A1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS. | GENENTECH INC (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991001331-A1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4349683-A | ANTICONVULSANTS, ANTIDEPRESSANTS | SYNTHELABO (FR) | 1982-09-14 | — | — | US | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | ALDH1A1 63/4885CYP2C9 152/4885CYP2C19 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.